<DOC>
	<DOC>NCT00148564</DOC>
	<brief_summary>The purpose of this study is to evaluate the effects of different atypical antipsychotics on weight changes, energy homeostasis, metabolism, energy intake as well as activity. Patients with schizophrenia or schizoaffective disorders will be randomly assigned to be treated with ziprasidone or olanzapine for 24 weeks. Primary outcome parameter are the weight changes after 24 weeks.</brief_summary>
	<brief_title>Energy Homeostasis Under Treatment With Atypical Antipsychotics</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Diagnosis of schizophrenia or related disorders(DSMIV) Indication for longterm treatment with antipsychotics BMI between 20 to 30 Weight changes less than 3kg in the last 3 months before inclusion Informed consent Psychiatric comorbidity Depot antipsychotic in the last 2 months Antipsychotics in the last 2 weeks Treatment with olanzapine, clozapine or ziprasidone in teh last 3 months Treatment with drugs, that may lead to weight changes Significant endocrine, neurological, cardiovascular, hepatic, renal, metabolic, or other medical diseases or any clinically relevant abnormalities in laboratory tests Female subjects during pregnancy and breastfeeding Female subjects within childbearing years who were not using adequate birth control Patients who are judged by the investigator to be at serious suicide risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>weight gain</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>atypical antipsychotics</keyword>
</DOC>